United States

Uveal melanoma
#Cancer research #FDA #iOnctura #Ophthalmology #Orphan drugs #United States

FDA grants orphan drug status for uveal melanoma drug

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation for iOnctura’s IOA-244, which is in development for solid and hematologic malignancies including uveal melanoma.  Uveal melanoma is a disease in which cancer originates in the tissues of the eye, causing symptoms such as blurred vision or a… Read More

#Cancer Research #News #Regulatory

Urinary system
#Bicycle Therapeutics #Cancer research #FDA #Oncology #United States

FDA fast-tracks metastatic urothelial cancer treatment

The United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Bicycle Therapeutics’ BT8009 monotherapy for the treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer.   BT8009 is a potential first in class Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a protein that… Read More

#Cancer Research #News #Regulatory #Trending News

US Food and Drug Administration
#Biologics / Biotechnology #Celltrion #Crohn's disease #FDA #Inflammatory Bowel Disease #Phase III trial #United States

First subcutaneous formulation of infliximab submitted to FDA

Celltrion USA has submitted a Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act for CT-P13 SC for the treatment of inflammatory bowel disease (IBD).  The submission is based on results from the Phase III pivotal data that evaluated the efficacy and safety of… Read More

#News #Regulatory

Doctor and patient
#Cell and gene therapy #Investment #Point of care services #United States

CGT company secures investment for point of care services

Orgenesis has agreed up to $50 million investment from Metalmark Capital in its US-based point of care services subsidiary, Morgenesis.  The investment will consist of an upfront investment of $30 million and two future investments of $10 million each, subject to the achievement of certain milestones.  Morgenesis will use the… Read More

#Business & Investment #News